Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15878587 | 0.88 | POLB (0.63) | POLBGAAKMT2ARAB9ANPC1 | |
| SCHEMBL15878586 | 0.88 | POLB (0.63) | POLBGAAKMT2ARAB9ANPC1 | |
| SCHEMBL15878585 | 0.88 | POLB (0.63) | POLBGAAKMT2ARAB9ANPC1 | |
| SCHEMBL15894490 | 0.88 | POLB (0.63) | POLBGAAKMT2ARAB9ANPC1 | |
| SCHEMBL23236621 | 0.87 | POLB (0.57) | POLBGAAKMT2ARAB9ANPC1 | |
| SCHEMBL15878151 | 0.87 | POLB (0.57) | POLBGAAKMT2ARAB9ANPC1 | |
| SCHEMBL15878150 | 0.87 | POLB (0.57) | POLBGAAKMT2ARAB9ANPC1 | |
| SCHEMBL15878149 | 0.87 | POLB (0.57) | POLBGAAKMT2ARAB9ANPC1 | |
| SCHEMBL15877734 | 0.87 | POLB (0.57) | POLBGAAKMT2ARAB9ANPC1 | |
| SCHEMBL891915 | 0.82 | POLB (1.00) | POLBGAAKMT2AMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163766-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7872009-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1954693-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007062007-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | POLB 2226/4885GAA 44/4885KMT2A 3113/4885 |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | POLB 2226/4885GAA 44/4885KMT2A 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.